In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, ...
Tags: psychiatric illness, psychotic disorders, rates of smoking
Health organisations around the world recommend a form of psychotherapy, known as cognitive-behavioural therapy or CBT, for patients with schizophrenia. Now, however, the most extensive study ever undertaken into its effect on the symptoms ...
Tags: psychotherapy, cognitive-behavioural therapy, schizophrenia
Shrunken structures inside the brains of heavy marijuana users might explain the stereotype of the "pothead," brain researchers report. Northwestern University scientists studying teens who were marijuana smokers or former smokers found ...
Tags: marijuana users, pothead, memory tasks, drug-related memory loss
Despite some concerns to the contrary, children whose moms used antidepressants during pregnancy do not appear to be at increased risk of autism, a large new Danish study suggests. The results, published Dec. 19 in the New England Journal ...
Tags: antidepressants, pregnancy, autism
Heavy pot users -- smoking marijuana daily for three years -- had abnormal changes in their brain structures related to working memory, U.S. researchers say. Lead study author Matthew Smith, an assistant research professor at Northwestern ...
Otsuka Pharmaceutical and H. Lundbeck have announced marketing authorization approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of ...
The Brain & Behavior Research Foundation (BBRF) (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of president and CEO Dr Jeffrey Borenstein, has announced the latest ...
Tags: Narsad, BBRF, investigator, award
Optivia Biotechnology has secured a $1.8m two-year Phase II small business innovation research (SBIR) grant, from the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH). The federal grant is expected to ...
Danish pharmaceutical company H. Lundbeck and Japanese drugmaker Otsuka Pharmaceutical have announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ...
Japanese drugmaker Otsuka Pharmaceutical has agreed to acquire Astex Pharmaceuticals for $866m in an all-cash tender offer. Under the deal, Astex's fragment-based drug design technology called 'PYRAMID' will be integrated into Otsuka, ...
Grupo Ferrer Internacional, Alexza Pharmaceuticals' commercial partner, has begun sales of Adasuve inhalation powder, pre-dispensed (Staccato Loxapine) in the European Union (EU). The first sale triggered a $1.25m milestone payment to ...
Tags: Inhalation Powder, Grupo
The US Food and Drug Administration (FDA) has cleared Omeros' investigational new drug application (IND) for OMS824 in Huntington's disease. OMS824 is developed to selectively inhibit phosphodiesterase 10 enzyme that is expressed in areas ...
Tags: Omeros'IND, Medicine
Johnson & Johnson's Pharmaceuticals unit Janssen is planning to submit more than 10 new products for regulatory approval and extend the brand pipeline of 25 existing drugs by 2017. The late stage products to be submitted for approval ...
Tags: Johnson&Johnson, New Drugs
Partek Incorporated has partnered with Kennedy Krieger Institute to develop commercial software, which will aid in analyzing genomic data from patients suffering with autism spectrum disorder and mental health disorders. Analyzing human ...
Tags: Partek, Kennedy Krieger Institute
Suven Life Sciences, a biopharmaceutical company, has received four product patents for its new chemical entities (NCEs). These patents represent the NCEs for the treatment of disorders associated with neurodegenerative diseases. The ...